BPC-157 — Body Protection Compound 157
Research evidence summary
also known as Body Protection Compound 157, PL 14736
BPC-157 is a synthetic 15-amino-acid peptide studied mainly in rodents. Human evidence is four small uncontrolled reports, and no dose has been established.
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- MW
- 1419.5 Da
- Discovered
- Early 1990s
- Receptor
- No receptor established; reviews describe effects on VEGFR2 (a receptor for a blood-vessel growth signal), the nitric oxide system and growth hormone receptor expression
- Half-life
- Under 30 minutes in rats and beagle dogs. A 2026 review says a two-person human pilot also showed under 30 minutes; the pilot's own stated methods are blood work and vital signs PubMed 36588717
Quoted from the source
the elimination half-life (t1/2) of prototype BPC157 was less than 30 min, and BPC157 showed linear pharmacokinetic characteristics in rats and beagle dogs at all doses.
- Routes in study
- IV (human pilot), Intravesical injection (human pilot), Intra-articular injection (human report), Submucosal injection with other agents (human case report), IP (rat studies)
What is BPC-157?
BPC-157, short for Body Protection Compound 157 and also written PL 14736, is a synthetic peptide of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with a molecular weight of about 1,419 (PMID 14554208). A 2026 review says it comes from a protein fragment in human gastric juice, was isolated and screened by Sikiric and colleagues at the University of Zagreb in the early 1990s, and is stable in human gastric juice. The same review reports that more than 80% of published BPC-157 studies, judged by author affiliation, come from that one Zagreb group (PMID 42198317). Several of the reviews cited below are also by that group.
What has been reported about how it works?
Mechanisms have been proposed from animal and cell studies. None has been shown in people.
- Cell migration. In cultured rat tendon fibroblasts, BPC 157 increased outgrowth from tendon explants, survival under oxidative stress and migration, and raised phosphorylation of two signalling proteins, FAK and paxillin (PMID 21030672). That abstract does not report VEGFR2 (vascular endothelial growth factor receptor 2, a receptor involved in making new blood vessels).
- Blood vessels and nitric oxide. A 2025 review says BPC-157 "activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis" (PMID 40789979). The originating group has reviewed its relation to the nitric oxide system in animal injury models (PMID 23755725).
- Growth hormone receptor. A 2025 systematic review of 36 studies, 35 of them preclinical, says the studies suggest BPC-157 "enhances growth hormone receptor expression" (PMID 40756949).
What has been studied in animals?
Tendon and ligament. In rats with a cut Achilles tendon, BPC 157 injected into the abdominal cavity (intraperitoneally) once daily at 10 µg, 10 ng or 10 pg per kg of body weight was reported to improve recovery on biomechanical, functional and microscopic measures against saline over 14 days (PMID 14554208). In a tendon-to-bone detachment model followed for 21 days, with the same doses and route, BPC 157 improved healing and "substantially reduces" the healing aggravation caused by a corticosteroid, 6alpha-methylprednisolone (PMID 16583442). In rat ligament transection followed for 90 days, it was reported effective given intraperitoneally, in drinking water or as a cream (PMID 20225319). A 2026 study of 32 rats with a repaired Achilles tendon gave 10 µg/kg/day intraperitoneally for four weeks; the result that reached significance was for a separate group given TB-500, and the combination added nothing (details on the comparison page; PMID 42542926).
Muscle. In rats with a calf-muscle crush injury, BPC 157 given intraperitoneally or as a cream was reported to heal muscle faster, including in animals given a corticosteroid; the authors concluded it "completely reversed" corticosteroid-impaired muscle healing (PMID 20190676).
Gut and wounds. A review by the originating group says BPC 157 was consistently effective across models of injury to the oesophagus, stomach, duodenum and lower gut when given intraperitoneally, by mouth or locally (PMID 29998800); a further review by the same group covers rat skin wounds (PMID 34267654).
How long it lasts in the body. In rats and beagle dogs, the elimination half-life was under 30 minutes after intravenous and intramuscular doses; intramuscular bioavailability was about 14 to 19% in rats and 45 to 51% in dogs (PMID 36588717). In people the sources conflict. A 2026 review says serial plasma sampling in a two-person intravenous pilot "demonstrated a half-life of under 30 min" (PMID 42198317), yet the pilot's own stated methods are blood work and vital signs before and after each infusion (PMID 40131143).
What has been studied in people?
Four small, uncontrolled reports have been published. Three are from private clinics with Lee E as first author; the fourth, from 2026, gave BPC-157 to three patients together with other drugs.
| Report | What was given | Who | What was reported |
|---|---|---|---|
| Lee 2021 (PMID 34324435) | Injection into the knee joint; the abstract gives no dose. BPC 157 alone for 12 patients, with thymosin beta-4 for 4 | Chart review of 17 patients in Orlando, Florida; 16 reached by phone | 11 of the 12 given BPC 157 alone reported significant improvement in knee pain. No tool measured function. A 2025 systematic review describes the same study as 7 of 12 with relief for more than 6 months (PMID 40756949). |
| Lee 2024 (PMID 39325560) | 10 mg in total around the inflamed area of the bladder during one cystoscopy; a compounding-pharmacy product | 12 women aged 39 to 76 with interstitial cystitis who had not responded to pentosan polysulfate | 10 reported complete resolution of symptoms and 2 rated their success at 80%, on a questionnaire. No adverse events were reported. No comparison group. |
| Lee 2025 (PMID 40131143) | 10 mg intravenously on day 1 and 20 mg on day 2, each over one hour | 2 adults, each of whom had received intravenous BPC-157 before | No measurable effects on tested markers of the heart, liver, kidneys, thyroid or blood glucose, and no side effects reported. |
| Froum 2026 (PMID 42876687) | Weekly submucosal injections for 4 weeks: BPC-157 1 mg, TB-500 10 mg and ARA-290 4 mg with dexamethasone 8 mg and bupivacaine each time | 3 patients with inferior alveolar nerve injury (nerve damage after dental problems or surgery) | Near-complete recovery with small residual deficits in cases 1 and 2 and about 95% less numbness in case 3. Its Table 1 lists adverse events as "None reported" for all three. |
The Froum authors say there was no control group, no randomisation and no standardised measurement of sensation, and that the other drugs make it impossible to tell which agent, or natural recovery, accounted for the outcome (published 30 September 2026). A 2026 systematic review searched to 1 June 2026 found only the first three studies (30 people), judged them to be of poor quality and rated the certainty of the evidence "very low" (PMID 42885452).
No controlled trial has been published. PubMed, (BPC-157[tiab] OR BPC157[tiab] OR "BPC 157"[tiab]) AND Clinical Trial[pt], 6 November 2026: 0 records; the same search with Randomized Controlled Trial[pt]: 0 records. A 2026 orthopaedic review, searched to June 2026, says human musculoskeletal evidence is limited to one small retrospective uncontrolled case series and that validated dosing, pharmacokinetic and long-term safety data are lacking (PMID 42937313).
Doses. No study has established a dose; the amounts above are the only published human ones, and the knee report gives none. Doses circulating online have not been tested in any published study; a 2026 review says doses used outside trials are "derived by informal extrapolation from the rodent dose range" (PMID 42198317).
Earlier work. The same review says early-phase clinical investigations for inflammatory bowel disease were run by Pliva (Croatia) under the codes PL-10, PLD-116 and PL14736, "providing limited but preliminary human tolerability data", and were not followed by Phase II or III trials (PMID 42198317).
Registered studies, none with posted results (ClinicalTrials.gov, 6 November 2026): NCT02637284, a phase 1 pilot of an oral tablet the record names as BPC-157 in an estimated 42 healthy volunteers, started October 2015, status unknown (the 2026 review says it was "terminated without publication of results"); NCT07803250, a phase 1 study at the University of Arkansas in 30 people after rotator cuff repair, not yet recruiting; and NCT07752381, a study of "peptide gummies containing Body Protection Compound (BPC)-157 (500 µg per serving)" in 40 participants, completed November 2025.
Risks and unknowns
- Human safety. The four reports cover 33 people with no comparison group. A 2026 case series of 32 men with hard flaccid syndrome reports that one patient experienced worsening after self-injection of the unapproved peptide BPC-157 into his penis outside of medical guidance (PMID 42871021). Its abstract does not name BPC-157, so a PubMed title or abstract search for BPC-157 does not return it. The four reports above include no harm report. A 2026 review says "the absence of reported adverse events in fewer than 30 subjects cannot be interpreted as evidence of safety in the pharmacological sense", and that none of the first three used a standardised pharmaceutical preparation (PMID 42198317).
- Tumour growth. BPC-157's proposed effects on VEGFR2 and VEGF (vascular endothelial growth factor, a blood-vessel growth signal) involve blood-vessel growth. The same review says "these properties raise a theoretical concern: BPC-157 could facilitate tumor vascularization in subjects with hidden or existing malignancy" (PMID 42198317).
- Animal toxicology. Preclinical evaluations have not identified a defined lethal dose or consistent organ-level toxicity signals, "although these findings remain limited to non-clinical settings". The toxicology studies described are mostly acute or short-term, there are no reproductive or developmental toxicity data, and genotoxic potential "has not been evaluated in standard Ames test or chromosomal aberration assays" (PMID 42198317). A 2020 preclinical study in mice, rats, rabbits and dogs reports no genetic or embryo-fetal toxicity, a fall in creatinine in dogs at 2 mg/kg (not at lower doses) that recovered within 2 weeks of stopping, and mild local irritation (PMID 32334036).
- Product quality. Commercial products "raise concerns regarding identity, purity, concentration, sterility, and manufacturing consistency" (PMID 42937313).
- FDA. FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) lists BPC-157 under "Bulk drug substances nominated but withdrawn", which it describes as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators". Compounding is the preparation of a medicine by a pharmacist or doctor from its ingredients. FDA's entry for BPC-157 reads: "Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans." A withdrawn-list entry is not a finding that the compound is safe. FDA's entry for "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500", given with BPC-157 in Froum 2026, is on the TB-500 page.
- Systematic review advice. The 2026 systematic review concluded that BPC-157 "should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials" (PMID 42885452).
UK regulatory position
This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.
Frequently asked questions
How does BPC-157 differ from TB-500 (thymosin beta-4)? BPC-157 is a 15-amino-acid peptide from a gastric protein fragment. A 2026 review describes TB-500 as "a distinct seven amino-acid fragment of TB-4 that is frequently conflated with full-length TB-4 despite the absence of validated biologic or clinical equivalence" (PMID 42937313).
Related on this site
- BPC-157 vs TB-500 — evidence comparison
- Stacks that include BPC-157: BPC-157 + TB-500 Healing Stack, BPC-157 + TB-500 + GHK-Cu Advanced Recovery, BPC-157 + KPV + Thymosin Alpha-1 Immune Stack, BPC-157 + GHK-Cu Hair Growth Stack, TB-500 + BPC-157 Tendon Repair Stack, Ipamorelin + CJC-1295 + BPC-157 Recomp Stack
- Angiogenesis & VEGFR2 mechanism map
- Wound healing phase mechanism map
- NF-κB inflammation mechanism map
- Time-dependent repair cascade
- Critical review of BPC-157 + TB-500 combination evidence
- Sikiric lab citation map
Regulatory and clinical status
UK status: No medicine label found (DailyMed name search, 6 November 2026). A 2026 systematic review describes it as lacking regulatory approval for human use. FDA safety statement: see Risks and unknowns.
Read what UK official sources say about medicines in our UK regulation hub and our explanation of why “research grade” does not mean safe. PeptideStacks does not make editorial sourcing recommendations within research content; any vendor links elsewhere on this page appear in a clearly-labelled sponsor block (see our conflict-of-interest disclosure).
References
Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. · Journal of Applied Physiology · 2011, 110(3), 774-780
- Model
- Rat Achilles tendon explants and cultured tendon fibroblasts
- Compound(s)
- BPC-157
- Outcome measured
- Fibroblast outgrowth from tendon explants, cell survival under oxidative stress, migration, FAK and paxillin phosphorylation
- Main finding
- BPC 157 accelerated outgrowth of tendon fibroblasts from explants, increased cell survival under oxidative stress and dose-dependently increased migration and FAK and paxillin phosphorylation in cultured cells.
- Key limitation
- Explant and cell-culture study; no animal healing outcome and no human data. Most BPC-157 evidence comes from a small number of laboratories.
Reported in study context only — not a recommendation or protocol.
- Pevec D, Novinscak T, Brcic L, et al.. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Medical Science Monitor. 2010;16(3) :BR81-88 · PMID: 20190676
- Seiwerth S, Milavic M, Vukojevic J, et al.. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021;12 :627533 doi:10.3389/fphar.2021.627533 · PMID: 34267654
- Seiwerth S, Rucman R, Turkovic B, et al.. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design. 2018;24(18) :1972-1989 doi:10.2174/1381612824666180712110447 · PMID: 29998800
- McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12) :611-619 doi:10.1007/s12178-025-09990-7 · PMID: 40789979
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021;27(4) :8-13 · PMID: 34324435
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024;30(10) :12-17 · PMID: 39325560
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5) :20-24 · PMID: 40131143
- Froum S, Estrin N, Pico G, et al.. Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Frontiers in Oral Health. 2026;7 :1907109 doi:10.3389/froh.2026.1907109 · PMID: 42876687
- Mendias CL, Awan TM. Multimodal rehabilitation for hard flaccid syndrome in a retrospective case series. Frontiers in Rehabilitation Sciences. 2026;7 :1970062 doi:10.3389/fresc.2026.1970062 · PMID: 42871021
- Xu C, Sun L, Ren F, et al.. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. 2020;114 :104665 doi:10.1016/j.yrtph.2020.104665 · PMID: 32334036
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthopaedica Belgica. 2026;92(3) doi:10.52628/92.3.15837 · PMID: 42885452
- Vasireddi N, Hahamyan H, Salata MJ, et al.. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4) :485-495 doi:10.1177/15563316251355551 · PMID: 40756949
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al.. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5) doi:10.3390/pharmaceutics18050625 · PMID: 42198317
- Tham A, Hodgkins CW, Kennedy JG. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. Journal of the American Academy of Orthopaedic Surgeons. 2026 doi:10.5435/JAAOS-D-26-00049 · PMID: 42937313
- He L, Feng D, Guo H, et al.. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022;13 :1026182 doi:10.3389/fphar.2022.1026182 · PMID: 36588717
- Staresinic M, Sebecic B, Patrlj L, et al.. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6) :976-83 doi:10.1016/S0736-0266(03)00110-4 · PMID: 14554208
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006;24(5) :982-9 doi:10.1002/jor.20096 · PMID: 16583442
- Cerovecki T, Bojanic I, Brcic L, et al.. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010;28(9) :1155-61 doi:10.1002/jor.21107 · PMID: 20225319
- Biçer O, Adanir O, Güleryüz Y, et al.. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. 2026;37(3) :822-837 doi:10.52312/jdrs.2026.2951 · PMID: 42542926
- Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157-NO-system relation. Current Pharmaceutical Design. 2014;20(7) :1126-35 doi:10.2174/13816128113190990411 · PMID: 23755725
- Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: a human dose range no study used was removed; the claim that no human safety data exist was replaced by four small uncontrolled reports and a harm report; FDA's safety statement was added; legal text was replaced.
If you spot an error or have new evidence to suggest, please use our corrections policy.
Research combinations referencing BPC-157
Combination evidence reviews on this site that include BPC-157 as one of their peptides.
BPC-157 + GHK-Cu — Research Evidence Review: Follicular Mechanisms & Evidence Limits
Evidence review of BPC-157 and GHK-Cu for hair: no study of the pair, no BPC-157 hair study, and one small published trial of GHK-Cu alone (eyebrows, 2026).
BPC-157 + KPV + Thymosin α-1 — Research Evidence Review: Immune & Mucosal Mechanisms
Evidence review of BPC-157, KPV and thymosin α-1: what has been studied in people, what thymosin α-1 trials found, and what is unknown about the three together.
BPC-157 + TB-500 + GHK-Cu — Research Evidence Review: Tissue-Repair & Remodelling Mechanisms
Evidence review of BPC-157, TB-500 and GHK-Cu for tissue repair: no study of the three together, one rat study of two found no added benefit, and little human evidence.
BPC-157 + TB-500 — Research Evidence Review: Tissue-Repair Mechanisms & Translational Limits
Evidence review of BPC-157 with TB-500: one rat study of the two together, one three-patient human report with other drugs, and what is unknown.
Ipamorelin + CJC-1295 + BPC-157 — Research Evidence Review: GH Axis + Tissue-Repair Mechanisms
Evidence review of ipamorelin, CJC-1295 and BPC-157: what has been studied in people and animals, and what is unknown. No study of the three together was found.
TB-500 + BPC-157 — Research Evidence Review: Tendon Repair Mechanisms & Study Models
Evidence review of BPC-157 and TB-500 in tendon repair: the rat studies, the one study that compared them with their combination, what is known in people, and what is unknown.
Continue reading
GHK-Cu — Copper Tripeptide-1
GHK-Cu is a copper-binding tripeptide used in skin-care products. Human trials are few, small and nearly all topical, and no human study of injected GHK-Cu alone was found.
TB-500 — Thymosin β-4 Fragment (Ac-LKKTETQ)
TB-500 is a synthetic seven-amino-acid fragment of thymosin β-4. Animal studies, one three-patient human report, how it differs from the full protein, and what is unknown.
BPC-157 vs TB-500 — Healing Peptide Comparison
BPC-157 vs TB-500: what animal and human studies have reported for each, and a 2026 rat study that compared them with their combination and found no added benefit.
Nitric oxide (NO) system
A gasotransmitter signalling system in which eNOS, iNOS and nNOS enzymes make nitric oxide from L-arginine, with roles in vascular tone, platelet function and tissue repair.
VEGF (Vascular Endothelial Growth Factor)
A family of secreted glycoproteins that drive angiogenesis, vasculogenesis, and vascular permeability by activating VEGF receptors on endothelial and progenitor cells.
VEGFR2
Vascular Endothelial Growth Factor Receptor 2, the primary signaling receptor mediating angiogenesis and endothelial cell survival downstream of VEGF.